Report Details:
15 Companies Covered
90 Pages
Advancements in Enzyme Replacement and Gene Therapies to Propel the Global Fabry Disease Market at a CAGR of 7.82% during the Forecast Period 2025–2035
Market Research Future (MRFR) has published a comprehensive research report on the “Global Fabry Disease Market,” covering the period from 2020 to 2035. The Global Fabry Disease Market is projected to register a CAGR of 7.82% during the forecast period of 2025 to 2035.
MRFR recognizes the following companies as the key players in the Global Fabry Disease Market: Amgen Inc., Amicus Therapeutics Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis AG, Pfizer Inc., Protalix, Takeda Pharmaceutical Company Limited, AVROBIO, Idorsia Pharmaceuticals Ltd., Sanofi, Shire, Teva Pharmaceutical Industries Ltd., iBio, and Neuraltus Pharmaceuticals.
Market Highlights
The Global Fabry Disease Market was valued at USD 2.44 billion in 2024 and is projected to reach USD 5.58 billion by 2035, growing at a CAGR of 7.82% during the forecast period.
Market growth is primarily driven by the rising prevalence of Fabry disease, advancements in enzyme replacement therapies (ERT), and the emergence of gene-based treatments. Increasing awareness, government support through orphan drug incentives, and growing R&D investments by 199 organizations worldwide are strengthening market expansion.
Recent regulatory milestones such as the FDA approval of Elfabrio for adult patients and the Fast Track Designation of isaralgagene civaparvovec underscore the rapid progress being made in developing novel treatment options.
Segment Insights
The Global Fabry Disease Market has been segmented based on Type, Diagnosis & Treatment, End Users, and Region.
Based on Type, the market is divided into Type 1 (Classic) and Type 2 (Later-Onset) Fabry disease. The Type 2 segment dominates, as studies suggest its prevalence is 3–10 times higher than that of Type 1 in certain male populations (Chien et al., 2012).
By Diagnosis & Treatment, Diagnosis includes blood tests, urine tests, thyroid tests, lung function tests, imaging (EKG, echocardiogram, brain MRI, CT scan), hearing and eye examinations, and others. The treatment segment—comprising enzyme replacement therapy (ERT), gene therapy, pharmaceutical formulations containing agalsidase alfa, analgesics, anticonvulsants, and NSAIDs—held the largest share in 2024. ERT remains the leading therapy type, with drugs like Fabrazyme and Replagal addressing the root cause of Fabry disease. In August 2021, Amicus Therapeutics received European Commission approval for Galafold (migalastat) in adolescents aged 12–16 years, expanding treatment access globally.
Based on End Users, the market is segmented into Hospitals & Clinics, Diagnostic Centers, Research & Academic Institutes, and Others. Hospitals & Clinics dominate the segment, supported by the increasing adoption of advanced diagnostics, government-backed infrastructure development, and the availability of skilled healthcare professionals.
Regional Analysis
By Region, the Global Fabry Disease Market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.
North America led the market in 2024, accounting for 45.8% of global revenue with USD 1.8 billion. The region’s dominance is attributed to strong healthcare infrastructure, favorable reimbursement policies, and the presence of major pharmaceutical players.
Europe held the second-largest share, driven by the adoption of advanced chaperone and enzyme therapies, with the UK and Germany being key contributors.
Asia-Pacific (APAC) is anticipated to be the fastest-growing regional market, supported by rising healthcare expenditure, expanding diagnostic capabilities, and government support for rare disease management.
The Rest of the World, including Latin America and the Middle East, is witnessing steady growth, driven by improved access to treatments and awareness campaigns.
Key Findings of the Study
- The Global Fabry Disease Market is projected to reach USD 5.58 billion by 2035, growing at a CAGR of 7.82% during 2025–2035.
- North America accounted for the largest share in 2024, while Asia-Pacific is expected to exhibit the fastest growth.
- Based on Treatment, Enzyme Replacement Therapy (ERT) held the largest market share in 2024.
- Increasing government support for rare disease funding, growing R&D activities, and new gene therapy developments are key growth drivers.
- Market players such as Amicus Therapeutics, Takeda, and Protalix are expanding their clinical pipelines through strategic collaborations and partnerships.